Silicon Valley billionaire Bryan Johnson, known for his extreme anti-aging experiments, has added a non-invasive radiofrequency device called Everesse to his routine. This device, marketed as Volnewmer in Taiwan, signals a shift from aggressive one-time treatments to long-term collagen management, a trend relevant for medical aesthetics buyers and distributors seeking devices that support sustained skin remodeling.
Market signal
Bryan Johnson, 48, has spent over $2 million annually on his "Project Blueprint" since 2021, including a vegan diet, hundreds of supplements, hyperbaric oxygen, and even plasma exchange with his son. His reported results—18-year-old lung capacity, 28-year-old skin, and 37-year-old heart—have drawn global attention. However, extreme fat loss led to a gaunt face, prompting his "Project Baby Face" using donor fat injections, which caused severe allergic swelling.
Device spotlight: Everesse (Volnewmer)
After the failed fat injection, Johnson shifted to a collagen-building strategy, incorporating Everesse, known in Taiwan as Volnewmer (海芙電波). The device features "dual-depth RF action," simultaneously heating superficial and deep dermal layers for comprehensive coverage. Unlike many RF devices using cryogen spray cooling, Volnewmer employs a continuous water-cooling system to protect the epidermis while maintaining a gradual thermal gradient.
Clinical rationale
Dr. Hsu Ying-ping of Tsui-Jiou Aesthetics Clinic explains that the device's cooling system allows the papillary dermis—responsible for type III collagen and skin texture—to reach the optimal 42–45°C range for repair signals, improving texture, pores, and fine lines without over-cooling. Post-treatment, collagen fibers contract for immediate tightening, with progressive neocollagenesis over months for lifting and volumizing effects, without significant downtime.
What buyers should watch
Johnson's adoption of Volnewmer reflects a global trend toward "collagen management" as a sustainable anti-aging strategy. For distributors and clinics, this device's dual-depth RF and water-cooling technology offer a differentiated value proposition in the competitive RF market. The emphasis on gradual, cumulative results aligns with growing demand for non-invasive, low-downtime solutions that support long-term patient loyalty.
Regulatory and channel signals
Everesse is marketed under the name Volnewmer in Taiwan and is available through authorized clinics. The device's inclusion in Johnson's public regimen may boost brand recognition and consumer interest in Asia-Pacific markets. Buyers should verify local regulatory approvals and OEM partnerships, as the device's technology could appeal to clinics seeking to expand their anti-aging device portfolio.
Source: Read the original report | Published: June 10, 2026